Publications by authors named "J Portnow"
Tumor heterogeneity is a significant factor influencing cancer treatment effectiveness and can arise from genetic, epigenetic, and phenotypic variations among cancer cells. Understanding how tumor heterogeneity impacts tumor evolution and therapy response can lead to more effective treatments and improved patient outcomes. Traditional bulk genomic approaches fail to provide insights into cellular-level events, whereas single-cell RNA sequencing (scRNA-seq) offers transcriptomic analysis at the individual cell level, advancing our understanding of tumor growth, progression, and drug response.
View Article and Find Full Text PDFBackground/objectives: Up to 30% of patients with breast cancers will develop brain or leptomeningeal metastases, and this risk is especially high with HER2-positive cancers. For patients with central nervous system metastases, cerebrospinal fluid (CSF) liquid biopsies are a promising opportunity to monitor disease, inform treatment, and predict prognosis. This pilot study investigated CSF liquid biopsy analytes from three patients diagnosed with central nervous system metastases based on imaging but not confirmed via clinical cytology.
View Article and Find Full Text PDFArticle Synopsis
- Eribulin is a microtubule dynamics inhibitor that shows potential for managing brain tumors, especially breast cancer brain metastases, due to its lower protein binding and resistance to P-glycoprotein extrusion.
- A clinical study involved administering eribulin to cancer patients post-tumor removal, with samples analyzed to measure its concentrations in the brain and plasma.
- Results indicated higher concentrations of eribulin in areas where the blood-brain barrier was disrupted, but overall levels in the brain were not enough to confirm consistent clinical effectiveness against brain tumors.